146 related articles for article (PubMed ID: 3493845)
1. Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.
Sato S; Fujiwara H; Kosugi A; Hamaoka T
Cancer Immunol Immunother; 1987; 24(2):121-6. PubMed ID: 3493845
[TBL] [Abstract][Full Text] [Related]
2. Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones.
Fujiwara H; Sato S; Kosugi A; Fukuzawa M; Hamaoka T
Cancer Immunol Immunother; 1987; 24(2):113-20. PubMed ID: 3493844
[TBL] [Abstract][Full Text] [Related]
3. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
[TBL] [Abstract][Full Text] [Related]
4. The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens.
Sano S; Izumi Y; Sugihara S; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(2):105-10. PubMed ID: 3499223
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.
Kosugi A; Shima J; Sano H; Ogata M; Kusama T; Fujiwara H; Hamaoka T
Infect Immun; 1986 Dec; 54(3):768-73. PubMed ID: 3491048
[TBL] [Abstract][Full Text] [Related]
6. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.
Hamaoka T; Takai Y; Kosugi A; Mizushima Y; Shima J; Kusama T; Fujiwara H
Cancer Immunol Immunother; 1985; 20(3):183-8. PubMed ID: 2933141
[TBL] [Abstract][Full Text] [Related]
7. Effect of helper T cells on prevention of tolerance induction in effector T cells responsible for syngeneic tumor immunity.
Fujiwara H; Kinouchi T; Tsuchida T; Aoki H; Hamaoka T
Gan; 1982 Oct; 73(5):766-72. PubMed ID: 6219908
[TBL] [Abstract][Full Text] [Related]
8. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
9. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of specific suppression in effector T cell clones against tumor-associated transplantation antigens.
Fujiwara H; Tsuchida T; Mizuochi T; Kohmo T; Hamaoka T
Gan; 1981 Oct; 72(5):732-41. PubMed ID: 7035282
[TBL] [Abstract][Full Text] [Related]
11. Tolerance induction in tumor-specific effector T cells by presensitization with tumor antigens via the intragastric route.
Hashimoto T; Okuno K; Tsuchida T; Fujiwara H; Hamaoka T
Gan; 1984 Jul; 75(7):610-6. PubMed ID: 6236126
[TBL] [Abstract][Full Text] [Related]
12. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.
Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736
[TBL] [Abstract][Full Text] [Related]
13. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
Takatsu K; Hamaoka T; Tominaga A; Kanamasa Y
J Immunol; 1980 Dec; 125(6):2367-73. PubMed ID: 6776192
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effect of portal venous inoculation with tumor cells on the anti-tumor immune potential.
Kokudo S; Qian JH; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1987 Sep; 78(9):946-51. PubMed ID: 3117751
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
[TBL] [Abstract][Full Text] [Related]
16. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
Kosugi A; Yoshioka T; Suda T; Sano H; Takahama Y; Fujiwara H; Hamaoka T
J Leukoc Biol; 1987 Dec; 42(6):632-41. PubMed ID: 2960766
[TBL] [Abstract][Full Text] [Related]
17. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
18. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
[TBL] [Abstract][Full Text] [Related]
19. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
Ueda S; Wakamiya N; Wu KS; Kato S; Fujiwara H; Hamaoka T
Biken J; 1984 Mar; 27(1):1-7. PubMed ID: 6385960
[TBL] [Abstract][Full Text] [Related]
20. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells.
Shimizu Y; Fujiwara H; Ueda S; Wakamiya N; Kato S; Hamaoka T
Eur J Immunol; 1984 Sep; 14(9):839-43. PubMed ID: 6236991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
